Unbound Cloxacillin Concentrations During Continuous Infusion
ConditionStaphylococcal Infections
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmeli Månsson
About this trial
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older
Treating physician has decided to start continuous infusion of cloxacillin
Disqualifiers
Unwilling or unable to provide written informed consent
Trial design
Design model
Single group
Treatments tested in this trial
Unbound cloxacillin concentration
Diagnostic testUnbound cloxacillin concentration measured at baseline, after 4h, after 24h and after 48h of continuous infusion.
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: Treatment with cloxacillin as continuous infusion via elastomeric pumpExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Free (unbound) cloxacillin concentration
Time frame
From enrollment to end of follow up at 48 hoursSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov